LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The present trial will investigate the efficacy and safety of nintedanib in combination with
docetaxel as compared to placebo in combination with docetaxel in patients with stage IIIB/IV
or recurrent NSCLC of adenocarcinoma histology after failure of first-line platinum-based
chemotherapy.